Josemir W. Sander
is now entering its ninth year and continues to do well.
We strive to disseminate news from the Executive Committee
and of epilepsy initiatives from around the world, and this
has been recognised by our membership. It was indeed very
pleasing for the editorial team to hear, at the Chapters convention
in Madrid, how highly regarded Epigraph is by our
Chapters. We are always trying to improve and to respond to
the expectations of our constituency. For instance, in response
to the feedback from the Madrid convention, we have launched
a "country focus" feature. This is an opportunity
for Chapters to contribute information about epilepsy initiatives
in their own country.
It is our intention that each issue of Epigraph is
personally delivered to all members. We are getting close
to this stage. We now have a complete set of mailing lists
for more than 30 countries, and members in these Chapters
are receiving their copy by post as soon as it is published.
As the compilation of a central database of ILAE members progresses
and more accurate contact details for our Chapters are acquired,
we hope to be able to deliver a personal copy to all members
throughout the world. Each issue of Epigraph is also
posted on the ILAE Website and we hope eventually to have
an electronic version sent to members who are interested in
receiving the publication in this way.
Since its onset, Epigraph has
been sponsored by Janssen-Cilag. This support, however, is
now coming to an end, and we would like to take this opportunity
to thank Janssen-Cilag for their generous unrestricted sponsorship
of Epigraph over the last eight years. Novartis,
to whom we are very grateful, has agreed to sponsor Epigraph
and we look forward to it going from strength to strength
under their sponsorship.